• METTL14-Mediated m6A Regulation in Ulcerative Colitis Inflam

  2026-05-13

  This study identifies METTL14 as a pivotal regulator of inflammation in ulcerative colitis (UC) by orchestrating m6A-dependent control over the DHRS4-AS1/miR-206/A3AR axis. The findings clarify epigenetic mechanisms underlying UC progression and highlight new molecular targets for therapeutic intervention.

• Miltefosine: Advancing Neutrophil Differentiation via Dual P

  2026-05-12

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) uniquely drives neutrophil differentiation by modulating both PI3K/Akt and Ras/MEK/ERK pathways. This guide integrates experimental best practices and troubleshooting to maximize translational impact in hematology research.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Protocol and Workflow

  2026-05-12

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) enables precise detection of HMGB1 chromatin protein in human, mouse, and rat samples for Western blot, immunohistochemistry, and flow cytometry research workflows. It is not validated for diagnostic or therapeutic use and should only be used in basic research settings where reliable chromatin protein detection is required.

• Triamcinolone: Technical Guidance for Synthetic Glucocortico

  2026-05-11

  Triamcinolone is a synthetic glucocorticoid agonist designed for controlled studies of glucocorticoid signaling, anti-inflammatory responses, and immunosuppression in vitro. It is not suitable for diagnostic or clinical use, and its specialized solubility and storage requirements demand careful workflow planning. Researchers should use Triamcinolone where precise modulation of glucocorticoid pathways is required and avoid use in medical applications.

• Miltefosine: Advancing Neutrophil Differentiation and PI3K/A

  2026-05-11

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) uniquely accelerates neutrophil differentiation by activating the Ras/MEK/ERK pathway, while simultaneously inhibiting the PI3K/Akt axis to modulate cell proliferation and survival. This dual-acting small molecule, available from APExBIO, is transforming both hematology and oncology experimental workflows.

• Triazole ALDH2 Activators for Myocardial Ischemia: Mechanist

  2026-05-10

  This article analyzes a recent study introducing novel triazole-based activators of aldehyde dehydrogenase 2 (ALDH2) with enhanced water solubility and unprecedented activation potency. The research provides strong preclinical evidence for these compounds as next-generation interventions for myocardial ischemia-reperfusion injury, especially in populations with ALDH2 dysfunction.

• APEX2 Proximity Labeling Reveals Pef1’s Role in DNA Repair a

  2026-05-09

  This study introduces APEX2-biotin phenol-mediated proximity labeling in Schizosaccharomyces pombe to systematically map the protein interaction landscape of the autophagy- and lifespan-regulating kinase Pef1, an ortholog of human CDK5. The findings uncover previously unrecognized Pef1 functions in DNA damage response and autophagosome expansion, establishing a framework for dissecting dynamic kinase interactomes in vivo.

• Patient-Derived Gastric Cancer Assembloids for Drug Response

  2026-05-08

  This study introduces a patient-derived gastric cancer assembloid system integrating matched tumor organoids with stromal cell subpopulations, achieving a more physiologically relevant tumor microenvironment than traditional models. The approach reveals critical influences of stromal cells on gene expression and drug response, supporting improved preclinical testing and personalized therapy development.

• Sulfaphenazole: Precision CYP2C9 Inhibition for Translationa

  2026-05-08

  Explore the mechanistic and translational significance of Sulfaphenazole as a selective CYP2C9 inhibitor, uncovering its roles in vascular function, oxidative stress reduction, and advanced wound healing. This article bridges the gap between molecular insight and strategic application, offering protocol recommendations and a forward-looking perspective for translational researchers.

• Lycopene Counters Deoxynivalenol-Induced Gut Barrier Damage

  2026-05-07

  This study demonstrates that lycopene effectively mitigates deoxynivalenol-induced intestinal barrier dysfunction and NLRP3 inflammasome activation in IPEC-J2 cells by targeting the ERK pathway. The findings offer mechanistic insight into the potential of dietary antioxidants to counteract mycotoxin-induced gut inflammation and epithelial injury.

• ATS-9R: Transforming Adipose Gene Silencing in Metabolic Dis

  2026-05-07

  This thought-leadership article explores how ATS-9R (Adipocyte-targeting sequence-9-arginine) redefines targeted gene delivery in metabolic disease research. By bridging mechanistic understanding with translational guidance, we examine prohibitin-mediated endocytosis, the unique workflow advantages of ATS-9R, and its translational promise for obesity-associated inflammation and insulin resistance models. Drawing on recent peer-reviewed evidence and expert workflow insights, this piece positions APExBIO’s ATS-9R as a pivotal tool for advancing adipocyte-focused therapeutics.

• Metabolic Enhancement of Ferroptosis and Cuproptosis in Tumo

  2026-05-06

  This article examines a recent metabolic intervention strategy that synchronously sensitizes tumor cells to ferroptosis and cuproptosis, thereby enhancing anti-tumor immunity. The study introduces a nanosystem targeting glycolysis and NAD+ metabolism, offering new mechanistic insights and practical routes for regulated cell death-based cancer therapy.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-05-06

  This study introduces a novel glabridin-gold(I) complex (6d) that synergistically targets thioredoxin reductase (TrxR) and MAPK pathways to enhance antitumor immunity while mitigating immunosuppression in liver cancer. The findings offer mechanistic insight into dual-pathway modulation and highlight prospects for improved combination immunotherapy strategies.

• L-Ornithine (B8919): Mechanistic Insights for CNS-Liver Rese

  2026-05-05

  Explore the multifaceted role of L-Ornithine in CNS-liver axis research, with new mechanistic insights from recent studies. This article highlights its value in advanced amino acid metabolism research and practical assay design.

• GANT61: GLI Inhibitor Workflows for Tumor Growth Suppression

  2026-05-05

  Leverage GANT61, a selective GLI inhibitor from APExBIO, to dissect Hedgehog pathway signaling, overcome immunotherapy resistance, and suppress tumor growth in advanced cancer models. This guide provides evidence-backed protocols, advanced troubleshooting, and actionable insights that translate the latest bench research into practical workflows.

15622 records 1/1042 page Next 12345 下5页 Last page